Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing hearing by The Stock Exchange of Hong Kong Limited for its initial public offering (IPO). While the price and other key details have not been disclosed at this stage, the company’s listing marks a significant step in its journey to expand its presence in the orthopedics, metabolic diseases, tumors, and hematology sectors, which together accounted for 51.5% of total drug sales in China in 2023.
Company Background and Focus Areas
Founded in 1993, Jiuyuan Gene has established itself as a key player in the orthopedics, metabolic diseases, tumors, and hematology treatment areas. The company’s focus on these areas reflects the growing demand for advanced treatments in China, underlining the importance of Jiuyuan Gene’s role in addressing these critical healthcare needs.
Diversified Product Portfolio and Market Firsts
Jiuyuan Gene boasts a diversified product portfolio that includes eight listed products, such as recombinant human bone morphogenetic protein-2 (rh BMP-2), which is the first of its kind in China. This product is a testament to the company’s commitment to innovation and leadership in the orthopedic space. Additionally, Jiuyuan Gene has over ten investigational drugs in its pipeline, including JY29-2, a biosimilar version of Novo Nordisk’s semaglutide that is awaiting regulatory decisions in China. The potential approval and launch of these drugs will further diversify Jiuyuan Gene’s offerings and strengthen its position in the market.-Fineline Info & Tech
Leave a Reply